Canada markets closed

Mind Cure Health Inc. (MCURF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3290+0.0149 (+4.73%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.3141
Open0.3480
BidN/A x N/A
AskN/A x N/A
Day's Range0.3090 - 0.3480
52 Week Range0.2540 - 0.6310
Volume291,742
Avg. Volume371,360
Market Cap30.249M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
    CNW Group

    MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

    Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that it has completed the first stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. Throughout this proof-of-concept stage, MINDCURE completed the chemistry and route scouting and successfully manufactured synthetic ibogaine.

  • Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer
    CNW Group

    Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

    Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the appointment of Dr. Joel Raskin as Chief Medical Officer. A trusted and respected leader in the neuroscience community, Dr. Raskin possesses two decades of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization.

  • MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor
    CNW Group

    MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children's Hospital, as Company Advisor

    Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the addition of Dr. John Brownstein as Advisor to the Company. Dr. Brownstein, the Chief Innovation Officer at Boston Children's Hospital and a Professor of Medicine at the Harvard Medical School, is world-renowned for his pioneering approach to data management and technology within health care. The HealthMap system he founded was the first electronic disease surveillance program to issue an alert for COVID-19 in late December of 2019. Dr. Brownstein and his team also run Vaccine Finder, a platform to help people more easily find clinics and pharmacies that offer COVID-19 vaccinations.